All of Us Research Program
Do you want to change the future of health? The Froedtert & MCW health network is part of the National Institutes of Health All of Us Research Program. It has a simple mission — speed up health research breakthroughs. To do this, All of Us is asking one million people to share their health information. Learn how you can help make a difference by joining the All of Us Research Program.
A Multi-Center, Open Label Phase 1/2 Study Of Cyt-0851, An Oral Rad51 Inhibitor, In Patients With Relapsed/Refractory B-Cell Malignancies And Advanced Solid Tumors
A Phase 1, First-in-Human, Dose Escalation Study of MGD006, a CD123 x CD3 Dual Affinity Re-Targeting (DART) Bi-Specific Antibody-Based Molecule, in Patients with Relapsed or Refractory Acute Myeloid Leukemia or Intermediate-2/High Risk Myelodysplastic Syndrome
• What are the side effects of MGD006?
• What is the highest dose of MGD006 that can be given safely?
• How long does MGD006 stay in the blood?
• How long does it take for MGD006 to leave the body?
• Is MGD006 a possible treatment for AML?
An Open-Label, Multicenter Phase 1b Study Investigating the Safety of TAK-079 in Combination with Backbone Regimens for the Treatment of Patients with Newly Diagnosed Multiple Myeloma and for Whom Stem Cell Transplantation Is Not Planned as Initial Therapy
If you are eligible to participate in this study, you will be assigned to receive either:
1) Arm A: TAK-079 (study medication), lenalidomide and dexamethasone (backbone regimen)
or
2) Arm B: TAK-079 (study medication), bortezomib, lenalidomide and dexamethasone (backbone regimen)
An Open-label, First-in-human, Single Agent, Dose Escalation and Expansion Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics and Antitumor Activity of SAR442085 in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
A Phase III, Randomized, Controlled, Double-Blind Study Evaluating the Safety of Two Doses of Apixaban for Secondary Prevention of Cancer Related Venous Thrombosis in Subjects Who Have Completed at Least Six Months of Anticoagulation Therapy
A Phase I/II, Open-label, Multicentre 2-part Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticle as Monotherapy or in Combination in Treatment-naïve or Relapsed/refractory Acute Myeloid Leukaemia/Myelodysplastic Syndrome Patients Not Eligible for Intensive Induction Therapy
A Phase 1, First-in-Human, Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 424 in Subjects with Multiple Myeloma
A Phase Ib/II, Open-label, Multicenter, Randomized, Controlled Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination with CHOP or CHP-Polatuzumab Vedotin in Patients with B-Cell Non-Hodgkin Lymphoma
A Multicenter, Phase 1, Open-label, Dose-escalation and Expansion Study of TNB-383B, a Bispecific Antibody Targeting BCMA in Subjects with Relapsed or Refractory Multiple Myeloma
A Phase I/II study to investigate the safety and clinical activity of GSK3326595 and other agents in subjects with myelodysplastic syndrome and acute myeloid leukaemia.
Phase I study of Pracinostat in Combination with Gemtuzumab Ozogamicin (PraGO) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)
A Phase 1/2 Study of Oral LOXO-305 in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin s Lymphoma (NHL)
Molecular Analysis for Therapy Choice (MATCH)
A Phase 1 Study with an Expansion Cohort of the Combination of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma
A Phase I Study of Lintuzumab-Ac225 in Patients with Refractory Multiple Myeloma
This is a phase I trial. The purpose of the study is to observe the safety, efficacy (good or bad) and determine the maximum dose of Lintuzumab-Ac225 that can be given to patients with multiple myeloma like you without causing bad effects.